ArticleBlood2011
Escape from highly effective public CD8+ T-cell clonotypes by HIV.
Article in Blood, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed, 110 citations in OpenAlex.
- Plasticity of the Immune System in Children Following Treatment Interruption in HIV-1 Infection.Frontiers in immunology · 2021Trial
- T-cell receptor sequencing demonstrates persistence of virus-specific T cells after antiviral immunotherapy.British journal of haematology · 2019Trial
- Functional avidity and IL-2/perforin production is linked to the emergence of mutations within HLA-B*5701-restricted epitopes and HIV-1 disease progression.Journal of immunology (Baltimore, Md. : 1950) · 2014Trial
- Persistence of EBV antigen-specific CD8 T cell clonotypes during homeostatic immune reconstitution in cancer patients.PloS one · 2013Trial
- Multistep coevolution of HIV-1 and human leukocyte antigen-C-restricted HIV-1-specific CD8PNAS nexus · 2026Article
- Vaccination Against Pathogens Targeting Cell-Derived Cryptic Antigens.The Journal of infectious diseases · 2026Article
- CD3 downregulation identifies high-avidity human CD8 T cells.Clinical and experimental immunology · 2024Article
- Recruitment of naive CD4+ T cells by the recombinant zoster vaccine correlates with persistent immunity.The Journal of clinical investigation · 2023Article
- KRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumors.Nature communications · 2023Article
- Viral infection reveals hidden sharing of TCR CDR3 sequences between individuals.Frontiers in immunology · 2023Article
- Adaptation to HLA-associated immune pressure over the course of HIV infection and in circulating HIV-1 strains.PLoS pathogens · 2022Article
- CD8 coreceptor engagement of MR1 enhances antigen responsiveness by human MAIT and other MR1-reactive T cells.The Journal of experimental medicine · 2022Article
- Reduction of CD8 T Cell Functionality but Not Inhibitory Capacity by Integrase Inhibitors.Journal of virology · 2022Article
- Epitope length variants balance protective immune responses and viral escape in HIV-1 infection.Cell reports · 2022Article
- Perturbations in the T cell receptor β repertoire during malaria infection in children: A preliminary study.Frontiers in immunology · 2022Article
- Structural Basis for Unusual TCR CDR3β Usage Against an Immunodominant HIV-1 Gag Protein Peptide Restricted to an HLA-B*81:01 Molecule.Frontiers in immunology · 2022Article
- Expansion of Unique Hepatitis C Virus-Specific Public CD8Journal of immunology (Baltimore, Md. : 1950) · 2021Article
- CD8Immunity · 2021Article
- CD8Nature reviews. Immunology · 2020Review
- Clinical and evolutionary consequences of HIV adaptation to HLA: implications for vaccine and cure.Current opinion in HIV and AIDS · 2019Review
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 10 institutions in 6 countries.
Funding
Abstract
Mapping the precise determinants of T-cell efficacy against viruses in humans is a public health priority with crucial implications for vaccine design. To inform this effort, we performed a comprehensive analysis of the effective CD8(+) T-cell clonotypes that constitute responses specific for the HIV p24 Gag-derived KK10 epitope (KRWIILGLNK; residues 263-272) restricted by HLA-B*2705, which are known to confer superior control of viral replication in HIV-infected individuals. Particular KK10-specific CD8(+) T-cell clonotypes, characterized by TRBV4-3/TRBJ1-3 gene rearrangements, were found to be preferentially selected in vivo and shared between individuals. These "public" clonotypes exhibit high levels of TCR avidity and Ag sensitivity, which impart functional advantages and enable effective suppression of HIV replication. The early L(268)M mutation at position 6 of the KK10 epitope enables the virus to avoid recognition by these highly effective CD8(+) T-cell clonotypes. However, alternative clonotypes with variant reactivity provide flexibility within the overall KK10-specific response. These findings provide refined mechanistic insights into the workings of an effective CD8(+) T-cell response against HIV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.